Clinical Trials Browser

Phase 2 × Lymphoma, B-Cell × pembrolizumab × Clear all

NCT06484920 2026-02-10

A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL

Phase 2 Recruiting

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT06242834 2026-01-14

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase 2 Recruiting

Lymphoma, B-Cell

NCT05507541 2025-08-29

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Active not recruiting

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03995147 2025-06-08

Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

Phase 2 Active not recruiting

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02332980 2024-01-03

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Phase 2 Completed

65 enrolled 21 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT03349450 2023-11-02

SPiReL

Phase 2 Completed

LymphoidSarcoma

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating